Asia Pacific Human Microbiome Market to 2025 - Regional Analysis and Forecasts by Product, Disease, Application, and Country

The Asia Pacific human microbiome market is expected to reach US$ 207.81 Mn in 2025 from US$ 41.73 in 2017. The market is estimated to grow with a CAGR of 22.8% from 2018-2025. The growth of the market is driven by the factors such as rising chronic disease due to change in lifestyle and growing interest in human microbiome treatment approach. Whereas, stringent regulatory environment and lack of awareness about human microbiome science is likely to have a negative impact on the growth of the market in the coming years.

Probiotics, prebiotics dietary supplements and foods that contain live microbes have been studied thoroughly to assess their effects on human health. The Gut Health Congress was held in Hong Kong Asia in 2018, the conference explore in detail of diet & personalised nutrition, gastrointestinal microbiome and several case studies with regards to clinical studies, diagnostics studies, treatment methods, biomarker developments, molecular therapy and gastrointestinal diseases. Also, the 5th Microbiome R&D and Business Collaboration Congress was held in Taiwan, Asia in March 2019, the conference focused on recent developments in gut microbiome, skin microbiome, infant, women and oral health, therapeutics, microbiome and diet.

Also, many companies are designing and developing many microbiome therapies. Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.

Japan is anticipated to lead the adoptions of Human microbiome across the Asia Pacific region through the forecast period. Researchers from Japan are using the outcomes of studies on centenarians in the country to try and produce new products that will replicate the beneficial aspects of their microbiota. The goal of the collaboration is to solve few of the major technological hurdles in advancing stem cell research. Moreover, Cykinso (Tokyo) received the US$ 2.3 million (270 million yen) funds from the Regional Health Care Industry Support Fund, develop and sell Mykinso or a test kit for intestinal flora. The company plans to use the funds for business development purposes, which include using the data collected from the intestinal flora tests to develop a system for offering nutritional guidance. Thus, the investments and the initiatives taken by the government are likely to propel the growth of the market in the forecast period.

Exhibit: Rest Of Asia Pacific Human microbiome Market Revenue and Forecasts to 2027 (US$ Bn)

ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATION

By Product
Probiotics
Foods
Prebiotics
Medical Foods
Diagnostic Device
Drugs
Supplements

ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATION

By Disease
Obesity
Diabetes
Autoimmune Disorders
Cancer
Mental Disorders
Others

ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATION

By Application
Therapeutics
Diagnostics

By Country
U.S.
Canada
Mexico

Companies Mentioned
Enterome
MicroBiome Therapeutics, LLC
Rebiotix Inc.
Yakult Honsha Co., Ltd.
Osel Inc.
Vedanta Biosciences, Inc.
Metabiomics Corporate
Synthetic Biologics, Inc.
DuPont
BiomX Ltd.